Moderna (NASDAQ:MRNA), Novavax (NASDAQ:NVAX), and other vaccine developers extended recent gains on Tuesday as investors reacted to rising flu and COVID-19 cases in the U.S. following the latest ...

Dosing can start once again in uniQure's phase 3 trial of its haemophilia B gene therapy, after the FDA ... shot therapy – expected before year-end in the US – as a result of the clinical hold.

has removed the clinical hold on Novavax's Investigational New Drug (IND) application for its COVID-19-Influenza Combination (CIC) and stand-alone influenza vaccine candidates. The FDA has cleared ...

Liver injuries also prompted the FDA to impose a partial clinical hold on Sanofi's BTK inhibitor tolebrutinib (SAR442168) earlier this year, holding up a programme that was a key part of its $3.7 ...

Following the mRNA-1083 vaccine, Moderna plans to develop a vaccine that simultaneously prevents COVID-19, influenza, and RSV. Novavax ... FDA to temporarily place the Phase 3 trial plan on hold ...

Inovio Pharmaceuticals Inc.-3.54% $71.48M ...

Find Flu Shot Covid stock video, 4K footage, and other HD footage from iStock. Get higher quality Flu Shot Covid content, for less—All of our 4K video clips are the same price as HD. Video Back Videos ...

Over 950 cases of H5N1 flu have been reported to the World Health Organization, half of which have resulted in death. Moderna and Novavax ... vaccine-focused stocks, especially to those who made ...

As influenza mutates rapidly, the most common strains change each flu season, and a new vaccine is required every year. The Centers for Disease Control and Prevention (CDC) estimates that there were ...

Moderna leads vaccine rally amid rising respiratory infections, spurring investment in COVID-19, flu, and RSV solutions. Recently, Zacks.com users have been paying close attention to Novavax (NVAX).

Potential Single-Dose Smallpox and Mpox Vaccine Moves Forward Nov. 13, 2024 — An FDA-approved ... Impact of COVID-19 Pandemic on Global Movement and Evolution of Seasonal Flu Nov.